Sai Parenteral's Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Sai Parenteral's Limited's achieved publicly listed status following its IPO debut on Apr 02, 2026 at the NSE, BSE platform. The offering successfully mobilized 1,04,28,288 Shares, with 72,70,408 Shares allocated to corporate growth initiatives and ₹123.79 Cr providing liquidity to existing shareholders.
Investment participation occurred within the established price band of ₹372 to ₹392, starting from minimum lots of 38 shares. The subscription window from Mar 24, 2026 through Mar 27, 2026 enabled investor participation across market segments.
Share allocation was completed on Mar 30, 2026, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical company engaged in the research, development, and manufacturing of formulations, operating across two main segments: branded generic formulations and contract development and manufacturing (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology, with offerings available in various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. The company serves a wide customer base including government agencies, pharmaceutical companies, hospitals, and distributors across India, and expanded into exports in FY 2023 after acquiring internationally accredited facilities in Hyderabad, enabling supply to markets like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral's operates five manufacturing facilities in India, four in Hyderabad and one through its wholly owned subsidiary Revat Laboratories in Ongole, Andhra Pradesh, all equipped with GMP and global certifications, and as of August 31, 2025, the company had 277 full-time employees.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Diversified Formulations Portfolio: Presence across multiple therapeutic segments and dosage forms reduces dependence on a single product.
- Accredited Manufacturing Facilities: WHO-GMP and international certifications like TGA and PIC/S enhance credibility and enable access to regulated markets.
- Strong CDMO Focus: CDMO capabilities support long-term contracts, better margins, and global partnerships.
- Geographical Concentration Risk: Manufacturing facilities are mainly located in Telangana and Andhra Pradesh, exposing operations to regional disruptions and regulatory changes.
- Dependence on Injectable Segment: A significant share of revenue comes from injectable products, increasing vulnerability to demand fluctuations in this segment.
- Regulatory Compliance Risk: Ongoing inspections and audits create risk, as any adverse findings may impact operations, reputation, and financial performance.
- Anil Kumar Karusala
- Vijitha Gorrepati
- Karusala Aruna
Sai Parenteral's Limited
Bigshare Services Private Limited